


PHARMACEUTICAL 2022

DiaMedica Therapeutics Inc. Rank 168 of 475









PHARMACEUTICAL 2022



DiaMedica Therapeutics Inc. Rank 168 of 475

The relative strengths and weaknesses of DiaMedica Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DiaMedica Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 254% points. The greatest weakness of DiaMedica Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -29%, being 247% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	45,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,524
Liabilities, Non-Current	3.0
Other Assets	42
Other Compr. Net Income	-49
Other Expenses	28
Other Liabilities	0
Other Net Income	82
Property and Equipment	70
Research and Development	8,765
Revenues	0
Selling, General and Administrative Expense	4,881

Output Variable	Value in 1000 USD
Assets	45,551
Liabilities	1,527
Expenses	13,674
Stockholders Equity	44,024
Net Income	-13,592
Comprehensive Net Income	-13,616
Economic Capital Ratio	-29%

